Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-10
2007-07-10
Page, Thurman K. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S464000
Reexamination Certificate
active
11475252
ABSTRACT:
The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
REFERENCES:
patent: 3819706 (1974-06-01), Nairman
patent: 4021492 (1977-05-01), Linder
patent: 4177291 (1979-12-01), Lindberg
patent: 4308400 (1981-12-01), Felder
patent: 4347257 (1982-08-01), Stern
patent: 4393078 (1983-07-01), Peck
patent: 4425363 (1984-01-01), Stern
patent: 4435449 (1984-03-01), Stern
patent: 4507323 (1985-03-01), Stern
patent: 4816489 (1989-03-01), Lafon
patent: 4980377 (1990-12-01), Lafon
patent: RE33994 (1992-07-01), Baker
patent: 5358970 (1994-10-01), Ruff
patent: 5427798 (1995-06-01), Ludwig
patent: 5731000 (1998-03-01), Ruff et al.
patent: 5753712 (1998-05-01), Pinsker
patent: 5968553 (1999-10-01), Maitra
patent: 6110973 (2000-08-01), Young
patent: 6150420 (2000-11-01), Houdi
patent: 6153223 (2000-11-01), Apelian
patent: 6197827 (2001-03-01), Cary
patent: 6210716 (2001-04-01), Chen
patent: 6221917 (2001-04-01), Maitra et al.
patent: 6280763 (2001-08-01), Midha
patent: 6306436 (2001-10-01), Chungi
patent: 6333332 (2001-12-01), Han
patent: 6337328 (2002-01-01), Fang
patent: 6458374 (2002-10-01), McCullough
patent: 6589553 (2003-07-01), Li et al.
patent: 6652882 (2003-11-01), Odidi
patent: 6734213 (2004-05-01), Partridge
patent: 6780871 (2004-08-01), Glick
patent: 6869942 (2005-03-01), Trofast et al.
patent: 6893660 (2005-05-01), Li
patent: 6932971 (2005-08-01), Bachmann
patent: 2001/0011103 (2001-08-01), McCullough
patent: 2001/0031784 (2001-10-01), Petersen et al.
patent: 2002/0173551 (2002-11-01), Reindler
patent: 2003/0035840 (2003-02-01), Li
patent: 2003/0073872 (2003-04-01), Atwood
patent: 2004/0059094 (2004-03-01), Bachmann
patent: 2004/0102440 (2004-05-01), Wong et al.
patent: 2004/0115263 (2004-06-01), Robertson
patent: 2004/0225020 (2004-11-01), McCullough
patent: 2005/0031670 (2005-02-01), Jamerson
patent: 2005/0143322 (2005-06-01), Gadde
patent: 2005/0176680 (2005-08-01), Lalji
patent: 2005/0238718 (2005-10-01), Oberegger
patent: 2005/0250838 (2005-11-01), Challapalli
patent: 2006/0099262 (2006-05-01), Chow
patent: WO 99/38502 (1999-08-01), None
patent: WO 01/68627 (2001-09-01), None
patent: WO 03/040121 (2003-05-01), None
patent: WO 2004/024674 (2004-03-01), None
patent: WO 2004/089873 (2004-10-01), None
Fava et al. “15 Years of Clinical Experience with Bupropion HCI:From Bupropion to Bupropion SR to Bupropion XL”. Prim. Care Companion J Clin Psychiatry 2005; 7 (3) pp. 106-113.
Berge et al. “Pharmaceutical Salts”. J. Pharm Sci. Jan. 1977; vol. 66 (1).
Stahl et al. “A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor”. Prim Care Companion, J Clin Psychiatry 2004; 6(4) pp. 159-166.
“CITALOPRAM”. http://www.answers.com/citalopram 4pages.
Remington's Pharmaceutical Sciences, 17thed. 1985 p. 1418.
Wikipedia® i Wikimedia Foundation, Inc http://en.wikipedia.org/wiki/Bupropion#History 20:57, Apr. 8, 2007.
Murray, et al., “Interaction of Dextrorotary Opioids with Phencyclidine Recognition Sites in Rat Brain Membranes”, Life Sci., vol. 34, p. 1899-1911, 1984.
Nishikawa, et al., “Evidence for, and Nature of, the Tonic Inhibitory of Habenulointerpeduncular Pathways upon Cerebral Dopaminergic Transmissionin the Rat”, Brian Res., vol. 373, p. 324-336, 1986.
Koyuncuoglu, et al., “The Treatment of Heroin Addicts with Dextromethorphan: A Double-blind Comparison of Dextromethrophan with Chlorpromazine”, Int. J. Clin. Pharmacol. Ther., vol. 28, p. 147-152, 1990.
Glick, et al., “Effects and aftereffects of ibogaine on morphine self-administration in rats”, Europ. J. Pharmacol., vol. 195, p. 341-345, 1991.
Flores, et al., “A Subtype of Nicotinic Cholinergic Receptor in Rat Brain is Comprised of 4 and 2 Subunits and is Up-regulated by Chronic Nicotine Treatment”, Mol. Pharmacol., vol. 41, p. 31-37, 1992.
Koyuncuoglu, “The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients”, Int. J. Clin. Pharmacol. Ther., vol. 33, No. 1, p. 13-19, Jan. 1995.
Popik, et al., “NMDA antagonist properties of the putative antiaddictive drug, ibogaine”, Pharmacology and Experimental Therapeutics, vol. 275, No. 2, p. 753-760, 1995.
Sweetnam, et al., “Receptor Binding Profile Siggest Multiple Mechanisms of Action Are Responsible for Ibogaine's Putative Anti-addictive Activity”, Psychopharmacology, vol. 118, p. 369-376, 1995.
Chen, et al., “Ibogaine block of the NDMA Receptor: in vitro and in vivo studies”, Neuropharmacology, vol. 35, No. 4, p. 423-431, Apr. 1996.
Glick, et al., “18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats”, Brain Res., vol. 719, vol. 1-2, p. 29-35, May 6, 1996.
Badio, et al., “Ibagaine: A Potent Noncopetitive Blocker of Ganglionic/Neuronal Nicotinic Receptors”, Molec. Pharmacol., vol. 51, p. 1-5, 1997.
Pulvirenti, et al., “Dextromethorphan reduces intravenous cocaine self-administration in the rat”, Eur. J. Pharmacol., vol. 321, No. 3, p. 279-283, Mar. 5, 1997.
Rezvani, et al., “Attenuation of Alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats”, Pharmacol. biochem. behav., vol. 58, No. 2, p. 615-619, 1997.
Ebert, et al. “Opioid Analgesics as noncompetitive N-mthyl-D-asparate (NMDA) Antagonists”, Biochem Pharmacol., vol. 56, No. 5, p. 553-559, Sep. 1, 1998.
Glick, et al., “Mechanism of Antiaddictive Actions of Ibogaine”, Annals of the New York Academy of Sciences, vol. 844, p. 214, 1998.
Mah, et al., “Ibogaine acts at the Nicotinic acetylcholine receptor to inhibit catecholamine release”, Brain Res., vol. 797, No. 1, p. 173-180, Jun. 22, 1998.
Fryer, et al., “Noncopetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine”, Pharmacology and Experimental Therapeutics, vol. 288, No. 1, p. 88-92, 1999.
Lukas, et al., “International Union of Pharmacology. XX. Current Status of the Nomenclature for Nicotinic Acetylcholine Receptors and their Subunits”, Pharmacology and Experimental Therapeutics, vol. 51, No. 2, p. 397-401, 1999.
Maisonneuve, et al., “Attenuation of the Reinforcing efficacy of morphine by 18-methoxycoronaridine”, Eur. J. Pharmacol., vol. 383, No. 1, p. 15-21, 1999.
Quick, et al., “3 4 Subunit-containing Nicotinic Receptors Dominate Function in Rat Medial Habenula Neurons”, Neuropsychopharmacology, vol. 38, p. 769-783, 1999.
Reid, et al., “A Nicotine antagonist, Mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects”, Neuropsychopharmacology, vol. 20, No. 3, p. 297-307, Mar. 1999.
Glick, et al., “18-MC reduces Methamphetamine and nicotine self-administration in rats”, Neuroreport, vol. 11, No. 9, p. 2013-2015, 2000.
Glick, et al., “18-Methoxycoronaridine (18-MC) and Ibogaine: Comparison of Antiaddictive Efficacy, Toxicity, and Mechanisms of Action”, Annals of the New York Academy of Sciences, vol. 914, 369-386, 2000.
Glick, et al., “Development of Novel Medication for Drug Addiction: The Legacy of an African Shrub”, Annals of the New York Academy of Sciences, vol. 909, p. 88-103, 2000.
Hernandez, et al., “Dextromethorphan and its Metabolite Dextrorphan Block 3 4 Neuronal Nicotinic Receptors”, J. Pharmacol, Exp. Ther., vol. 293, p. 962-967, 2000.
Jun, et al., “Dextromethorphan Alters methamphetamine self-administration in the rat”, Pharmacol. Biochem. Behav., vol. 67, No. 3, p. 405
Jackson Graham
Maes Paul
Massardo Pietro
Oberegger Werner
Saleh Mohammad Ashty
Biovail Laboratories, Inc.
Hunton & Williams LLP
Lao MLouisa
Page Thurman K.
LandOfFree
Modified release formulations of a bupropion salt does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified release formulations of a bupropion salt, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified release formulations of a bupropion salt will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3806394